China’s Shenzhen Salubris Pharmaceuticals Co., Ltd (SHE: 002294) has entered into a partnership with Beijing Anlong Biopharmaceutical Co., Ltd to jointly research and develop small nucleic acid drugs for the treatment of hypertension. The collaboration aims to leverage the combined expertise of both companies in the field of nucleic acid drug development.
Partnership Details
Under the agreement, Anlong Bio will be responsible for early-stage development, utilizing its proprietary ANOG small nucleic acid drug technology platform. Salubris will handle late-stage development, clinical trials, and marketing efforts, and will hold exclusive global research and development and commercialization rights to any emerging small nucleic acid drugs. The two companies will share market and commercial interests in the future. Financial specifics of the deal were not disclosed.
Company Backgrounds
Founded in 2019, Anlong Bio is known for its proprietary ANOG small nucleic acid drug technology platform, which includes the Gal Mola nucleic acid drug delivery vector, AP oligonucleotide modification, and AAV Luc transgenic animal screening model. These technologies enable the development of a series of liver-targeting and extrahepatic small nucleic acid drugs. Salubris Pharma, founded in 1998 in Shenzhen, operates multiple R&D centers in China and the US, focusing on the development of innovative pharmaceuticals.-Fineline Info & Tech
